Key points are not available for this paper at this time.
Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme; CLEAR ClinicalTrials.gov number, NCT02811861.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Motzer et al. (Sat,) studied this question.
www.synapsesocial.com/papers/69d7c01a3b601d7be3ae2ae9 — DOI: https://doi.org/10.1056/nejmoa2035716
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
Robert J. Motzer
B. Yа. Alekseev
Sun Young Rha
New England Journal of Medicine
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
The University of Queensland
Building similarity graph...
Analyzing shared references across papers
Loading...